Become one of the exclusive investors taking DAVIGOworx public!
The investment company DAVIGOworx GmbH & Co KGaA is on the verge of a significant step: It is offering a "stock exchange-ready" share for issuance, whose investment strategy is fully developed and tested. To successfully complete the IPO, DAVIGOworx is seeking investors who will provide callable capital through a private placement.
Completed investments
from the practical test portfolio*
DECIPHERA PHARMACEUTICALS IN
NEOGAMES SA
HIBBETT INC
ALPINE IMMUNE SCIENCES INC
SHOCKWAVE MEDICAL INC
SOVOS BRANDS INC
TEXTAINER GROUP HOLDINGS LTD
DISCOVER FINANCIAL SERVICES
MASONITE INTERNATIONAL CORP
CYMABAY THERAPEUTICS INC
MCGRATH RENTCORP
QIAGEN N.V.
OVERSEAS SHIPHOLDING GROUP-A
ENGAGESMART INC
INHIBRX INC
KAMAN CORP
MDC HOLDINGS INC
CARROLS RESTAURANT GROUP INC
FIRST FINANCIAL NORTHWEST
ANSYS INC
JUNIPER NETWORKS INC
AXONICS INC
ENETI INC
DASEKE INC
KARUNA THERAPEUTICS INC
CEREVEL THERAPEUTICS HOLDING
ALTERYX INC - CLASS A
PGT INNOVATIONS INC
UNITED STATES STEEL CORP
ICOSAVAX INC
IMMUNOGEN INC
VERITIV CORP
ROVER GROUP INC
VMWARE INC-CLASS A
ARGO GROUP INTERNATIONAL
NEW RELIC INC
BLUEGREEN VACATIONS HOLDING
TABULA RASA HEALTHCARE INC
SPIRIT REALTY CAPITAL INC
FIESTA RESTAURANT GROUP
CIRCOR INTERNATIONAL INC
HERITAGE-CRYSTAL CLEAN INC
ACTIVISION BLIZZARD INC
NATIONAL INSTRUMENTS CORP
PIONEER NATURAL RESOURCES CO
MIRATI THERAPEUTICS INC
NATIONAL WESTERN LIFE GROU-A
SP PLUS CORP
HORIZON THERAPEUTICS PLC
LIVEVOX HOLDINGS INC
*Past returns are not an indicator of future returns.
For the acquisition of publicly listed company shares, DAVIGOworx utilizes its self-developed software "Yield Finder." This investment technology has been extensively used in a practical test portfolio since August 2018. Since then, a total of 2,222 company shares (as of April 30, 2024) have been acquired and subsequently sold – with very positive results. The average profit per sold company share in the practical test portfolio was 62.6 percent as of April 30, 2024, with an average holding period per company share of 2.1 years. This corresponds to an average of 25.4 percent p.a. per investment. These were almost exclusively U.S. companies included in broad U.S. indices.
DAVIGOworx is revolutionizing the investment market with a unique publicly traded stock that innovatively bridges public equity and private markets.
We will bundle thousands of company holdings into a single, liquid security, making diversified investing accessible to everyone.
Our data-driven approach combines the strengths of public equity and private markets: while we primarily focus on small and mid-caps in the public equity sector, the private markets segment will feature a balanced portfolio across vintages, stages, regions, and sectors – developed in collaboration with VC/PE experts.
This agile combination of both asset classes will enable the stabilization and maximization of capital efficiency while ensuring daily tradability – a key advantage over traditionally illiquid private markets investments.
The transparency and easy integration into existing investment policies make us particularly attractive to institutional investors, while private investors benefit from the opportunity to comprehensively diversify their portfolio with a single stock.
Our goal is to establish the DAVIGOworx stock as an essential component in every investor’s portfolio. Become an exclusive investor in DAVIGOworx and help shape the future of diversified investing – with a scalable, forward-thinking investment solution that eliminates the divide between public equity and private markets.
Questions and Answers
DAVIGOworx is the revolutionary stock that will unite public equity and private markets in a single, liquid security. Thousands of company holdings, a data-driven approach, and daily tradability will make DAVIGOworx the future of diversified investing. Whether you’re a private investor or an institutional investor – with DAVIGOworx, you’ll experience how we break down the boundaries between traditional asset classes and take every (!) portfolio to the next level.
Our primary goal is initially to enter the general over-the-counter market. However, this is just the beginning: We aim to transition to the higher-tier over-the-counter market plus XETRA as quickly as possible to further strengthen our market position and become more attractive to a broader range of investors.
The path to going public follows clearly defined steps. First, we secure investors who provide callable capital through a private placement. Once the listing requirements for the general over-the-counter market are met, we call in the capital commitments, allowing investors to subscribe to DWRX24 shares. A few days later, the listing will commence.
After the IPO, we will focus on a strategy of continuous growth. We plan regular capital increases, supported by massive marketing towards retail investors and targeted engagement with institutional partners such as issuing banks and selling agents. Our goal is to steadily increase the liquidity of DAVIGOworx stock and make it attractive to an increasingly broader range of investor groups.
Note
The information on this website represents promotional preliminary information for a planned public offering of shares by DAVIGOworx GmbH & Co. KGaA in the form of a private placement using the prospectus exemption under Art. 1 Para. 4 lit c) Regulation (EU) 2017/1129. The standard minimum subscription amount shall be EUR 1 million, in no case less than EUR 100,000. The information on this website is not sufficient to make a purchase decision and does not replace complete and final information from DAVIGOworx GmbH & Co. KGaA. Therefore, the information on this website does not constitute an offer to purchase shares.
Warning: The acquisition of shares involves substantial risks and may lead to the complete loss of invested capital.